Table 2 Predictors of week 16 endpoint scores for individual arms, after controlling for baseline scores
| Â | Placebo Group n= 46 | Active Treatment Group n= 47 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Flushes | Greene Climacteric Scale | HDI-17 | Flushes | Greene Climacteric Scale | HDI-17 | ||||||
|  | β (SE) | p- value | β (SE) | p- value | β (SE) | p- value | β (SE) | p- value | β (SE) | p- value | β (SE) | p- value |
Age at trial start | 0.03 (0.28) | 0.93 | -0.26 (0.24) | 0.28 | -0.39 (0.17) | 0.03 | 0.38 (0.32) | 0.25 | -0.21 (0.25) | 0.41 | 0.23 (0.19) | 0.24 |
Previous Herb Med effective | -10.9 (0.07) | 0.63 | -3.07 (1.84) | 0.10 | -3.14 (1.37) | 0.03 | -1.80 (3.04) | 0.56 | -4.46 (2.40) | 0.07 | -2.27 (1.88) | 0.23 |
Attitude to menopause | -0.63 (2.18) | 0.77 | 0.66 (1.88) | 0.73 | -0.24 (1.45) | 0.87 | -3.30 (2.97) | 0.27 | -4.54 (2.09) | 0.04 | -3.16 (1.60) | 0.055 |
GCS score, study entry | -0.53 (0.17) | 0.003 | -0.43 (0.16) | 0.012 | -0.38 (0.13) | 0.007 | 0.23 (0.26) | 0.37 | 0.38 (0.26) | 0.15 | 0.36 (0.18) | 0.03 |
GCS anxiety, study entry | -0.97 (0.44) | 0.03 | -0.82 (0.39) | 0.04 | -0.33 (0.32) | <.001 | 1.16 (0.47) | 0.016 | 0.65 (0.44) | 0.14 | 0.68 (0.31) | 0.02 |
Change in GCS scores during run-in | -0.02 (0.04) | 0.59 | -0.15 (0.06) | 0.013 | -0.07 (0.02) | 0.005 | -0.04 (0.08) | 0.68 | 0.13 (0.08) | 0.13 | -0.07 (0.05) | 0.15 |